Cystic Fibrosis

"Cystic Fibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.

Descriptor ID	D003550
MeSH Number(s)	C06.689.202 C08.381.187 C16.320.190 C16.614.213
Concept/Terms	Cystic Fibrosis Cystic Fibrosis Fibrosis, Cystic Mucoviscidosis Pulmonary Cystic Fibrosis Pulmonary Cystic Fibrosis Cystic Fibrosis, Pulmonary Pancreatic Cystic Fibrosis Pancreatic Cystic Fibrosis Cystic Fibrosis, Pancreatic Fibrocystic Disease of Pancreas Pancreas Fibrocystic Disease Pancreas Fibrocystic Diseases Cystic Fibrosis of Pancreas

Below are MeSH descriptors whose meaning is more general than "Cystic Fibrosis".

Diseases [C]
Digestive System Diseases [C06]
Pancreatic Diseases [C06.689]
Cystic Fibrosis [C06.689.202]
Respiratory Tract Diseases [C08]
Lung Diseases [C08.381]
Cystic Fibrosis [C08.381.187]
Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Genetic Diseases, Inborn [C16.320]
Cystic Fibrosis [C16.320.190]
Infant, Newborn, Diseases [C16.614]
Cystic Fibrosis [C16.614.213]

Below are MeSH descriptors whose meaning is related to "Cystic Fibrosis".

Below are MeSH descriptors whose meaning is more specific than "Cystic Fibrosis".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cystic Fibrosis" by people in this website by year, and whether "Cystic Fibrosis" was a major or minor topic of these publications.

Bar chart showing 21 publications over 14 distinct years, with a maximum of 3 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	2	0	2
2002	1	0	1
2003	1	0	1
2006	1	1	2
2010	1	0	1
2012	1	0	1
2014	1	0	1
2015	1	0	1
2016	1	0	1
2017	2	1	3
2018	2	0	2
2019	1	1	2
2020	1	0	1
2021	0	2	2

Below are the most recent publications written about "Cystic Fibrosis" by people in Profiles.

King M, Kubo A, Kafer L, Braga R, McLeod D, Khanam S, Conway T, Patrauchan MA. Calcium-Regulated Protein CarP Responds to Multiple Host Signals and Mediates Regulation of Pseudomonas aeruginosa Virulence by Calcium. Appl Environ Microbiol. 2021 04 27; 87(10).

View in: PubMed
Biesecker LG, Adam MP, Alkuraya FS, Amemiya AR, Bamshad MJ, Beck AE, Bennett JT, Bird LM, Carey JC, Chung B, Clark RD, Cox TC, Curry C, Dinulos MBP, Dobyns WB, Giampietro PF, Girisha KM, Glass IA, Graham JM, Gripp KW, Haldeman-Englert CR, Hall BD, Innes AM, Kalish JM, Keppler-Noreuil KM, Kosaki K, Kozel BA, Mirzaa GM, Mulvihill JJ, Nowaczyk MJM, Pagon RA, Retterer K, Rope AF, Sanchez-Lara PA, Seaver LH, Shieh JT, Slavotinek AM, Sobering AK, Stevens CA, Stevenson DA, Tan TY, Tan WH, Tsai AC, Weaver DD, Williams MS, Zackai E, Zarate YA. A dyadic approach to the delineation of diagnostic entities in clinical genomics. Am J Hum Genet. 2021 01 07; 108(1):8-15.

View in: PubMed
Bernard KA, Vachon A, Pacheco AL, Burdz T, Wiebe D, Beniac DR, Hiebert SL, Booth T, Doyle DA, Lawson P, Bernier AM. Pseudoxanthomonas winnipegensis sp. nov., derived from human clinical materials and recovered from cystic fibrosis and other patient types in Canada, and emendation of Pseudoxanthomonas spadix Young et al. 2007. Int J Syst Evol Microbiol. 2020 Dec; 70(12):6313-6322.

View in: PubMed
Faraj J, Bodas M, Pehote G, Swanson D, Sharma A, Vij N. Novel cystamine-core dendrimer-formulation rescues ?F508-CFTR and inhibits Pseudomonas aeruginosa infection by augmenting autophagy. Expert Opin Drug Deliv. 2019 02; 16(2):177-186.

View in: PubMed
Christian F, Thierman A, Shirley E, Allen K, Cross C, Jones K. Sustained Glycemic Control With Ivacaftor in Cystic Fibrosis-Related Diabetes. J Investig Med High Impact Case Rep. 2019 Jan-Dec; 7:2324709619842898.

View in: PubMed
Lonabaugh KP, O'Neal KS, McIntosh H, Condren M. Cystic fibrosis-related education: Are we meeting patient and caregiver expectations? Patient Educ Couns. 2018 10; 101(10):1865-1870.

View in: PubMed
Bodas M, Mazur S, Min T, Vij N. Inhibition of histone-deacetylase activity rescues inflammatory cystic fibrosis lung disease by modulating innate and adaptive immune responses. Respir Res. 2018 01 04; 19(1):2.

View in: PubMed
Miller JL, Lepa TM, Ranallo C, Chaaban H, Skrepnek GH, Johnson PN. Detectable Concentrations of Inhaled Tobramycin in Critically Ill Children Without Cystic Fibrosis: Should Routine Monitoring Be Recommended? Pediatr Crit Care Med. 2017 Dec; 18(12):e615-e620.

View in: PubMed
Brockman SM, Bodas M, Silverberg D, Sharma A, Vij N. Dendrimer-based selective autophagy-induction rescues ?F508-CFTR and inhibits Pseudomonas aeruginosa infection in cystic fibrosis. PLoS One. 2017; 12(9):e0184793.

View in: PubMed
Sharpton R, Condren M, O'Neal K, Lloyd A, McIntosh H. Do cystic fibrosis patients on azithromycin need electrocardiogram monitoring? Pulm Pharmacol Ther. 2017 04; 43:55-56.

View in: PubMed

People

Explore

Similar Concepts

Top Journals